제놀루션

225220KOSDAQ기초 의약물질 제조업

61.0 / 100

Reference Date: 2026-04-13

Financial Score23.5 / 40

News Sentiment17.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly up 2.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Genolux operates in the molecular diagnostic equipment and RNAi research sectors, offering automated nucleic acid extraction devices and RNA synthesis services. The company has developed the world's first RNAi-based treatment for foulbrood disease in bees and obtained product approval, while expanding its RNAi-based agricultural pest control technologies.

Number of Employees

76people

Average Salary

53.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

0.51Industry Average 2.037.0Point

Half of industry avg (excellent)

ROE

-16.98Industry Average -4.293.5Point

4.0x industry avg (excellent)

Debt Ratio

0.44Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.6% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 1Negative 0Average Sentiment Score 85

Positive
제놀루션, 이탈리아 뷰티 박람회 '코스모프로프' 참가 성료
제놀루션은 이탈리아 뷰티 박람회 '코스모프로프 볼로냐'에 참가하여 글로벌 화장품·뷰티 산업 관계자들과의 교류를 통해 성과를 거두었습니다.
Positive
제놀루션, 소나무재선충병 방제용 RNAi 기술 특허 출원
제놀루션은 소나무재선충병 정밀 방제를 위한 핵심 RNA 간섭(RNAi) 기술의 국내 특허를 출원하며 산림 분야까지 그린바이오 사업 확장을 본격화했습니다.
Neutral
"상담액 168억"…K-동물용의약품, 동남아 수출 기대감 키웠다
이 기사는 한국동물약품협회의 태국 '아시아 건강·영양 박람회' 참가 성과를 다루고 있으며, 제놀루션이 한국관에 참가했으나 직접적인 계약이나 성과는 언급되지 않았습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 1,794Won52-week high 2,64552-week low 1,616

1-month return4.0Point

1m +2.57% (slight rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-08
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
Neutral감사보고서제출2026-03-19
Neutral사업보고서 (2025.12)2026-03-19
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-18